Patents Assigned to Institute Pasteur
  • Selective Inhibition of Nf-Kappab Activiation by Peptides Designed to Disrupt Nemo Oligomerization
    Publication number: 20080242601
    Abstract: The present invention relates to polypeptides that inhibit the NF-&kgr; B signaling pathway and polynucleotides encoding the same. The present invention further provides methods for the modulation of and/or treatment of inflammatory responses, oncogenesis, viral infection; the regulation of cell proliferation and apoptosis; and regulation of B or T lymphocytes in antigenic stimulation, by administering the polypeptides of the present invention to a subject in need thereof. Finally, the present invention provides a method of identifying polypeptides that modulate oligomerization of NEMO.
    Type: Application
    Filed: September 24, 2004
    Publication date: October 2, 2008
    Applicants: Institute Pasteur, Inserm (Inst.Nat.de la Sante et de la Rech.Med., CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Fabrice Agou, Gilles Courtois, Alain Israel, Michel Veron, Francois Traincard, Shoji Yamaoka, Yves-Marie Coic, Francoise Baleux
  • Therapeutic use of the SMR1 protein and active derivatives thereof
    Patent number: 7429448
    Abstract: The present invention pertains to the use of a peptide molecule consisting in a maturation product of SMR1 (Submandibular rat protein 1) of structural formula QHNPR, as well as the biologically active derivatives of the said peptide, for preventing or treating diseases associated with a mineral ion imbalance in a human or an animal body. More particularly, the present invention relates to the therapeutic use of the above-cited molecules for preventing or treating an hydro-mineral imbalance in organs and tissues such as kidney, bone, dental enamel, dental ivory, gut matrix, pancreas or glandular gastric mucosa. This invention also deals with therapeutic compositions comprising a pharmaceutically active amount of the above-described therapeutic molecules as well as with therapeutic methods using the said therapeutic compositions.
    Type: Grant
    Filed: July 17, 2003
    Date of Patent: September 30, 2008
    Assignee: Institut Pasteur
    Inventors: Catherine Rougeot, Francois Rougeon
  • IMMUNOGENIC GLYCOPEPTIDES, SCREENING, PREPARATION AND USES
    Publication number: 20080233599
    Abstract: The invention concerns immunogenic glycopeptides derived from pathogenic microorganisms, useful for vaccination and diagnosis of infections caused by said pathogenic microorganisms (bacteria or fungi), and methods for selecting them and preparing them.
    Type: Application
    Filed: February 21, 2008
    Publication date: September 25, 2008
    Applicant: INSTITUT PASTEUR
    Inventors: Gilles Marchal, Felix Romain, Pascale Pescher
  • Method of treating cytomegalovirus with DC-SIGN blockers
    Patent number: 7427469
    Abstract: The present invention relates to methods and compositions for preventing or treating diseases of a mammal, including viral infections, wherein at least one symptom of the disease is mediated at least in part by the binding of an effector molecule to a DC-SIGN receptor present on cells of the mammal to be treated. The invention also provides methods of identifying compositions, wherein the compositions are useful for treating mammalian diseases, including viral infections, for which at least one symptom of the disease is mediated at least in part by the specific binding of an effector molecule to a DC-SIGN receptor present on the cells that express the DC-SIGN receptor, belonging to the mammal to be treated. The invention further relates to compositions and methods for targeting subject molecules to cells that express the DC-SIGN receptor.
    Type: Grant
    Filed: November 5, 2003
    Date of Patent: September 23, 2008
    Assignee: Institut Pasteur
    Inventors: Ali Amara, Frank Halary, Julie Dechanet-Merville, Jean-Francois Moreau, Fernando Arenzana-Seisdedos, Thierry Delaunay
  • Treatment of mood disorders by administration of SMR1
    Patent number: 7423020
    Abstract: This invention relates to the use of an agent that modulates the interaction between a SMR1 peptide and a metal-lopeptidase for the preparation of a medicament for preventing or treating a Central Nervous System disorder giving rise to a mental disorder.
    Type: Grant
    Filed: December 24, 2001
    Date of Patent: September 9, 2008
    Assignees: Institut Pasteur, Centre National de la Recherche Scientifique (C.N.R.S)
    Inventors: Catherine Rougeot, Francois Rougeon
  • DNA sequences encoding peptide sequences specific for the hepatic stages of P. falciparum bearing epitopes capable of stimulating the T lymphocytes
    Publication number: 20080213795
    Abstract: The invention discloses isolated DNA sequences encoded by polypeptides characterized by the presence in their structure of one or more sequences bearing all or part of the one or more T epitopes, and possibly other epitopes, particularly B epitopes, characteristic of proteins resulting from the infectious activity of P. falciparum in hepatic cells.
    Type: Application
    Filed: December 20, 2007
    Publication date: September 4, 2008
    Applicant: INSTITUT PASTEUR
    Inventors: Claudine Guerin-Marchand, Pierre Druilhe
  • SECRETED CHLAMYDIA POLYPEPTIDES, POLYNUCLEOTIDES CODING THEREFOR, THERAPEUTIC AND DIAGNOSTIC USES THEREOF
    Publication number: 20080213285
    Abstract: The present invention relates to secreted Chlamydia polypeptides, which may be expressed by a Gram-negative bacterial strain and secreted by the type III secretion pathway of said bacterial strain. The present invention also relates to polynucleotides coding for these polypeptides, as well as to the therapeutic and vaccination uses of these secreted Chlamydia polypeptides.
    Type: Application
    Filed: October 23, 2007
    Publication date: September 4, 2008
    Applicant: INSTITUT PASTEUR
    Inventors: Agathe SUBTIL-SANDS, Alice DAUTRY-VARSAT
  • Chimeric GFP-aequorin as bioluminescent Ca++ reporters at the single cell level
    Publication number: 20080213879
    Abstract: A modified bioluminescent system comprising a fluorescent molecule covalently linked with a photoprotein, wherein said link between the two proteins has the function to stabilize the modified bioluminescent system and allowing the transfer of the energy by Chemiluminescence Resonance Energy Transfer(CRET).
    Type: Application
    Filed: June 10, 2005
    Publication date: September 4, 2008
    Applicants: Institut Pasteur, Centre National de la Recherche Scientifique
    Inventors: Valerie Baubet, Herve Le Mouellic, Philippe Brulet
  • Method of inhibiting binding of Dengue virus to a human cell with DC-SIGN blockers
    Patent number: 7419789
    Abstract: The present invention relates to methods and compositions for preventing or treating diseases of a mammal, including viral infections, wherein at least one symptom of the disease is mediated at least in part by the binding of an effector molecule to a DC-SIGN receptor present on cells of the mammal to be treated. The invention also provides methods of identifying compositions, wherein the compositions are useful for treating mammalian diseases, including viral infections, for which at least one symptom of the disease is mediated at least in part by the specific binding of an effector molecule to a DC-SIGN receptor present on the cells that express the DC-SIGN receptor, belonging to the mammal to be treated. The invention further relates to compositions and methods for targeting subject molecules to cells that express the DC-SIGN receptor.
    Type: Grant
    Filed: November 5, 2003
    Date of Patent: September 2, 2008
    Assignee: Institut Pasteur
    Inventors: Ali Amara, Fernando Arenzana-Seisdedos, Philippe Despres, Jean-Louis Virelizier
  • Peptides Derived from Human Bplp Protein, Polynucleotides Coding for Said Peptides and Antibodies Directed Against Said Peptides
    Publication number: 20080206230
    Abstract: The invention relates to a peptide that is a maturation product of the Basic Prolin-rich Lacrinal Protein (BPLP) or a peptide derivative of said maturation product, wherein the peptide or peptide derivative exhibits an inhibitory property against a metallo-ectopeptidase, especially NEP and/or APN. The present invention also relates to polynucleotides coding for said peptides and to antibodies directed against said peptides. Furthermore, the present invention relates to diagnostic and therapeutic uses of human BPLP protein and inhibitory peptides derived therefrom, polypeptides coding for human BPLP protein or peptides derived therefrom as well as antibodies directed against BPLP protein or peptides derived therefrom.
    Type: Application
    Filed: March 18, 2005
    Publication date: August 28, 2008
    Applicant: Institut Pasteur
    Inventors: Catherine Rougeot, Jean-Francois Huaulme, Marie-Noelle Ungeheuer, Anne Wisner, Evelyne Dufour
  • SELECTIVE INHIBITION OF NF-kappaB ACTIVIATION BY PEPTIDES DESIGNED TO DISRUPT NEMO OLIGOMERIZATION
    Publication number: 20080207517
    Abstract: The present invention relates to polypeptides that inhibit the NF-?B signaling pathway and polynucleotides encoding the same. The present invention further provides methods for the modulation of and/or treatment of inflammatory responses, oncogenesis, viral infection; the regulation of cell proliferation and apoptosis; and regulation of B or T lymphocytes in antigenic stimulation, by administering the polypeptides of the present invention to a subject in need thereof. Finally, the present invention provides a method of identifying polypeptides that modulate oligomerization of NEMO.
    Type: Application
    Filed: April 24, 2008
    Publication date: August 28, 2008
    Applicant: INSTITUT PASTEUR
    Inventors: Fabrice AGOU, Gilles Courtois, Alain Israel, Michel Vernon, Francois Traincard, Shoji Yamaoka
  • Method of diagnosis/prognosis of human chronic lymphocytic leukemia comprising the profiling of genes
    Patent number: 7416851
    Abstract: The present invention provides methods of diagnosis and prognosis of human chronic lymphocytic leukemia (CLL) in a subject a patient in need thereof. The methods of the present invention involve measuring the expression profile of two known genes: LPL and ADAM29; and comparing the ratio of their expression to diagnose the presence of CLL or to prognose the likelihood of developing CLL or the symptoms consistent with CLL.
    Type: Grant
    Filed: November 8, 2004
    Date of Patent: August 26, 2008
    Assignee: Institut Pasteur
    Inventors: Frederic Davi, Guillaume Dighiero, Gerard Dumas, Pablo Oppezzo, Catherine Settegrana, Yuri Vasconcelos Pinheiro
  • Methods for obtaining thermostable enzymes, DNA polymerase I variants from having new catalytic activities, methods for obtaining the same, and applications of the same
    Patent number: 7417133
    Abstract: The present invention provides a method for obtaining thermostable enzymes. The present invention also provides variants of DNA polymerase I from Thermus aquaticus. The present invention further provides methods of identifying mutant DNA polymerases having enhanced catalytic activity. The present invention also provides polynucleotides, expression systems, and host cells encoding the mutant DNA polymerases. Still further, the present invention provides a method to carry out reverse transcriptase-polymerase chain reaction (RT-PCR) and kits to facilitate the same.
    Type: Grant
    Filed: February 27, 2004
    Date of Patent: August 26, 2008
    Assignee: Institut Pasteur
    Inventors: Jean-Luc Jestin, Sophie Vichier-Guerre
  • Identification of substances that inhibit NEMO oligomerization
    Patent number: 7413863
    Abstract: The present invention provides methods for screening for substances which inhibit the oligomerization of NEMO and/or IKK-related complexes and/or signaling pathways based on the interference with NEMO oligomerization.
    Type: Grant
    Filed: June 8, 2007
    Date of Patent: August 19, 2008
    Assignee: Institut Pasteur
    Inventors: Francois Traincard, Fabrice Agou, Michel Veron
  • Descendants of bacteria devoid of N terminal formylation useful for the production of proteins and peptides
    Patent number: 7399611
    Abstract: Eubacterial cells which produce non-formylated proteins, polypeptides and/or peptides and methods for making such non-formylated products. The eubacterial cells may be produced by inactivating or deleting the def (deformylase) and/or fmt (Met-tRNA transformylase) gene(s) from the def-fmt operon of the corresponding wild-type strain.
    Type: Grant
    Filed: July 8, 2005
    Date of Patent: July 15, 2008
    Assignee: Institut Pasteur
    Inventors: Philippe Marliere, Rupert Mutzel, Didier Mazel
  • Method for modulating Nod1 activity, use of a MTP related molecule for modulating Nod1 activity, and therapeutic applications thereof
    Patent number: 7396812
    Abstract: A method for modulating Nod1 activity wherein said method comprises the steps of providing cells expressing a functional Nod1; and bringing said cells into contact with a molecule related to compositions comprising a molecule related to MTP and use of a molecule related to MTP for modulating inflammation and/or apoptosis.
    Type: Grant
    Filed: March 29, 2004
    Date of Patent: July 8, 2008
    Assignees: Institut Pasteur, Institut National de la Sante et de la Recherche Medicale
    Inventors: Philippe Sansonetti, Stephen Girardin, Dana Philpott, Ivo Boneca
  • Method for binding, in solution, a peptide and a lipophilic vector and uses thereof
    Patent number: 7390875
    Abstract: The invention concerns a method for binding, in solution, at least a peptide composition and at least a lipophilic vector bearing an aldehyde function, the coupling comprising a step which consists in producing a hydrazone bond between the peptide compound and the lipophilic vector. The invention also concerns lipophilic vectors for use in this method, lipopeptides obtained by this method, uses of the lipopeptides for cell screening, and the applications of the invention, in particular for preparing targeting of an active principle of the peptide kind (for example hormone or neuropeptide) through physiological barriers such as cell membranes.
    Type: Grant
    Filed: September 7, 2001
    Date of Patent: June 24, 2008
    Assignee: Institut Pasteur de Lille
    Inventors: Dominique Bonnet, Line Bourel, Oleg Melnyk, Hélène Gras-Masse
  • Neurovirulent strain of the West Nile virus and uses thereof
    Patent number: 7390495
    Abstract: Neuroinvasive and neurovirulent strain of the West Nile virus, named IS-98-ST1, nucleic acid molecules derived from its genome, proteins and peptides encoded by said nucleic acid molecules, and uses thereof.
    Type: Grant
    Filed: October 4, 2004
    Date of Patent: June 24, 2008
    Assignees: Institut Pasteur, Kimron Veterinary Institute
    Inventors: Philippe Despres, Vincent Deubel, Jean-Louis Guenet, Marie-Therese Drouet, Mertyn Malkinson, Caroline Banet, Marie-Pascale Frenkiel, Marie-Pierre Courageot, Fasseli Coulibaly, Adeline Catteau, Marie Flamand, Patrick Weber, Pierre-Emmanuel Ceccaldi
  • NF-?B peptides designed to disrupt NEMO oligomerization
    Patent number: 7390872
    Abstract: The present invention relates to polypeptides that inhibit the NF-?B signaling pathway and polynucleotides encoding the same. The present invention further provides methods for the modulation of and/or treatment of inflammatory responses, oncogenesis, viral infection; the regulation of cell proliferation and apoptosis; and regulation of B or T lymphocytes in antigenic stimulation, by administering the polypeptides of the present invention to a subject in need thereof. Finally, the present invention provides a method of identifying polypeptides that modulate oligomerization of NEMO.
    Type: Grant
    Filed: September 24, 2004
    Date of Patent: June 24, 2008
    Assignee: Institut Pasteur
    Inventors: Fabrice Agou, Gilles Courtois, Alain Israel, Michel Veron, Francois Traincard, Shoji Yamaoka
  • Therapeutic methods and compositions for the treatment of impaired interpersonal and behavioral disorders
    Patent number: 7387778
    Abstract: The invention relates to the field of psychopharmacology. More particularly, the invention relates to the treatment of mental disorders, such as impaired interpersonal and behavioral disorders, including sexual disorders such as M.E.D. and H.S.D.D. The invention provides new therapeutic compositions and methods for treating mental disorders, including M.E.D. and H.S.D.D. The compositions and methods according to the invention provide improved awareness and alertness to environment, improved adaptation to environment and ability to sustain attention, and increased interest in environment and capacity for arousal, without increased aggressiveness.
    Type: Grant
    Filed: December 21, 2001
    Date of Patent: June 17, 2008
    Assignees: Institut Pasteur, Centre National de la Recherche Scientifique
    Inventors: Tony Marcel, François Rougeon, Catherine Rougeot